Patent ID: 7994222

Claim:
A method of monitoring a therapeutic effectiveness of a compound of formula Ia or metabolite thereof or pharmaceutically acceptable salt thereof in a treatment of a fatty acid synthesis related disease selected from the group consisting of obesity, diabetes, or cardiovascular disease comprising: (i) administering an effective amount of a compound of formula Ia or metabolite thereof or pharmaceutically acceptable salt thereof to a patient to inhibit fatty acid synthesis; (ii) comparing a first and a second level of fatty acid in a first and second sample from said patient wherein said first level and said first sample are obtained prior to administration of said compound of formula Ia or metabolite thereof or pharmaceutically acceptable salt thereof and said second level and said second sample are obtained after administration of said compound of formula Ia or metabolite thereof or pharmaceutically acceptable salt thereof; and (iii) determining a therapeutic effectiveness of said compound of formula Ia or metabolite thereof or pharmaceutically acceptable salt thereof in a treatment of a disease in said patient based on said comparison, wherein the compound formula Ia is a compound of the formula: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are, independently selected from the group consisting of hydrogen, hydroxy, amino, nitro, iodo, bromo, fluoro, chloro, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 3 -C 7 ) cycloalkyl, and phenyl, wherein at least two of the five R 1 , R 2 , R 3 , R 4 , and R 5 substituents are always hydrogen, at least one of the five substituents is always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, or a metabolite thereof or a pharmaceutically acceptable salt thereof.